Reshma Kewalramani (Vertex Pharmaceutical Inc CEO since 2020, joined 2018) purchased $2.0 million of stock on the 19th August at $195.65, increasing his holding by 16%. This is a notable trade as it is his first buy since joining the company and he has been a regular seller of options and stock via 10b5-1 program sales.
Bruce Sachs (Lead Independent Director since 1998) bought $3.0 million of stock on the 2nd of August, despite his long tenure this is only his 2nd purchase in the stock since 2008.
These purchases from rare buyers are very encouraging.
We are ranking the stock +1.